What is Donanemab: Uses, Dosage, Side Effects and More

Donanemab is a breakthrough medication designed to slow the progression of Alzheimer's disease in its early stages. This innovative treatment works by targeting and removing amyloid plaques from the brain, which are believed to play a key role in Alzheimer's development. While it's not a cure, donanemab offers new hope for people facing this challenging condition by potentially helping preserve memory and thinking abilities for longer periods.

What is Donanemab?

Donanemab is a monoclonal antibody medication specifically engineered to fight Alzheimer's disease. Think of it as a targeted therapy that seeks out and attacks the harmful protein deposits in your brain called amyloid plaques. These sticky clumps accumulate between brain cells and are thought to interfere with normal brain function.

The medication belongs to a new class of Alzheimer's treatments called anti-amyloid therapies. Unlike traditional Alzheimer's medications that only manage symptoms, donanemab actually targets what researchers believe is one of the underlying causes of the disease. This represents a significant shift in how we approach Alzheimer's treatment.

Donanemab is administered through intravenous infusion, meaning you'll receive it directly into your bloodstream through an IV line. The treatment is typically given in a healthcare facility where medical professionals can monitor you closely during and after each infusion.

What is Donanemab Used For?

Donanemab is specifically approved for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease. It's designed for people in the early stages of the condition when symptoms are just beginning to affect daily life. The medication works best when Alzheimer's is caught early, before significant brain damage has occurred.

Your doctor will only prescribe donanemab if tests confirm you have amyloid plaques in your brain. This typically involves specialized brain scans or spinal fluid tests that can detect these protein deposits. The presence of these plaques is essential because the medication specifically targets them.

It's important to understand that donanemab isn't recommended for people with more advanced Alzheimer's disease. Research shows the medication is most effective when brain function is still relatively intact, giving it the best chance to slow further decline.

How Does Donanemab Work?

Donanemab works like a precision-guided system that identifies and removes harmful amyloid plaques from your brain. The medication contains specially designed antibodies that recognize these protein deposits and mark them for removal by your immune system. This process helps clear away the sticky buildup that interferes with brain cell communication.

The medication is considered a moderately strong treatment for Alzheimer's disease. While it's more powerful than traditional symptom-management drugs, it works gradually over time rather than providing immediate dramatic changes. Most people notice subtle improvements in maintaining their current abilities rather than experiencing significant recovery.

Clinical studies show that donanemab can slow cognitive decline by approximately 22% compared to a placebo. This means you might maintain your current level of thinking and memory skills for several additional months, giving you more quality time with loved ones and maintaining independence longer.

How Should I Take Donanemab?

Donanemab is given as an intravenous infusion every four weeks at a healthcare facility. Each treatment session lasts about 30 minutes, during which the medication is slowly delivered through an IV line in your arm. You'll need to plan for additional time before and after the infusion for preparation and monitoring.

Before each treatment, you don't need to avoid food or follow special dietary restrictions. However, it's helpful to eat a light meal beforehand to prevent any discomfort during the infusion. Make sure you're well-hydrated by drinking plenty of water in the hours leading up to your appointment.

Your healthcare team will monitor you closely during each infusion and for at least an hour afterward. They'll check your vital signs and watch for any immediate reactions. It's normal to feel tired after treatment, so consider having someone drive you home from your first few sessions.

You'll also need regular brain MRI scans throughout your treatment to monitor for a potential side effect called brain swelling. These scans help your doctor ensure the medication is working safely and adjust your treatment plan if needed.

How Long Should I Take Donanemab For?

Most people take donanemab for about 12 to 18 months, though the exact duration depends on how well you respond to treatment. Your doctor will monitor your progress through regular cognitive tests and brain scans to determine the optimal treatment length. The goal is to achieve maximum plaque removal while minimizing potential risks.

Some people may be able to stop treatment sooner if brain scans show significant plaque reduction. Others might benefit from continuing treatment for the full recommended period. Your individual response to the medication will guide these decisions, and your doctor will discuss the best approach based on your specific situation.

After completing treatment, you'll continue with regular follow-up appointments to monitor your cognitive function. While the medication's effects may continue for some time after stopping, your doctor might recommend other treatments to help maintain your cognitive abilities.

What Are the Side Effects of Donanemab?

Understanding potential side effects can help you feel more prepared and confident about your treatment. Most people tolerate donanemab well, but like all medications, it can cause some unwanted effects that range from mild to more serious.

The most common side effects you might experience include:

• Infusion-related reactions like headache, nausea, or dizziness during or shortly after treatment
• Brain swelling (called ARIA-E), which affects about 24% of people and is usually detected on routine MRI scans
• Small brain bleeds (called ARIA-H), which occur in approximately 31% of people but are often symptom-free
• Fatigue and feeling generally unwell for a day or two after infusion
• Mild confusion or temporary worsening of existing cognitive symptoms

These common side effects are typically manageable and often improve as your body adjusts to the treatment. Your healthcare team will monitor you carefully and can provide supportive care if needed.

More serious but less common side effects require immediate medical attention. These include:

• Severe headaches that don't respond to over-the-counter pain relievers
• Sudden confusion, disorientation, or significant changes in behavior
• Vision changes, including double vision or visual disturbances
• Seizures or loss of consciousness
• Severe nausea and vomiting that prevents you from keeping fluids down
• Difficulty speaking or understanding speech
• Weakness on one side of your body

If you experience any of these serious symptoms, contact your healthcare provider immediately or seek emergency medical care. Early recognition and treatment of these side effects can prevent more serious complications.

Who Should Not Take Donanemab?

Donanemab isn't suitable for everyone, and your doctor will carefully evaluate whether it's right for you. People with advanced Alzheimer's disease typically don't benefit from this treatment because significant brain damage has already occurred. The medication works best when brain function is still relatively intact.

You should not take donanemab if you have certain genetic factors that increase your risk of brain swelling. People with two copies of the APOE4 gene face a much higher risk of serious brain swelling and bleeding. Your doctor will likely test for this genetic variant before starting treatment.

Other conditions that may prevent you from using donanemab include:

• History of stroke or significant brain bleeding
• Severe kidney or liver disease that affects medication processing
• Active infections or compromised immune system
• Certain blood clotting disorders
• Pregnancy or breastfeeding
• Severe heart conditions that make regular monitoring difficult

Your doctor will review your complete medical history and current medications to ensure donanemab is safe for you. This thorough evaluation helps prevent complications and ensures you receive the most appropriate treatment.

Donanemab Brand Name

Donanemab is marketed under the brand name Kisunla by Eli Lilly and Company. When you receive your prescription or see it listed on medical documents, you might see either name used interchangeably. Both refer to the same medication with identical active ingredients and effects.

The brand name Kisunla was chosen to reflect hope and connection, which aligns with the medication's goal of helping people maintain their cognitive abilities and connections with loved ones. You might also see the technical name "donanemab-azbt" in some medical literature, which refers to the specific formulation used in clinical trials.

Donanemab Alternatives

Several other medications are available for treating Alzheimer's disease, though they work through different mechanisms than donanemab. Lecanemab (Leqembi) is the most similar alternative, as it also targets amyloid plaques in the brain. Like donanemab, it's given through IV infusion and is approved for early-stage Alzheimer's disease.

Traditional Alzheimer's medications include donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). These drugs work by increasing certain brain chemicals rather than removing plaques. They're often used for mild to moderate Alzheimer's disease and can be taken as pills or patches.

Memantine (Namenda) is another option, typically prescribed for moderate to severe Alzheimer's disease. It works by regulating brain activity and can be used alone or combined with other Alzheimer's medications. Your doctor will help determine which treatment approach is best for your specific situation.

Is Donanemab Better Than Lecanemab?

Both donanemab and lecanemab are effective treatments for early Alzheimer's disease, but they have some important differences. Donanemab may offer the advantage of shorter treatment duration, typically 12-18 months compared to ongoing treatment with lecanemab. This could mean fewer infusions and less time spent in healthcare facilities.

Clinical studies suggest donanemab might slow cognitive decline slightly more than lecanemab, but both medications show meaningful benefits. The choice between them often depends on your individual risk factors, treatment preferences, and how your body responds to each medication.

Your doctor will consider factors like your genetic profile, other health conditions, and personal preferences when recommending between these options. Both medications require regular monitoring and carry similar risks of brain swelling and bleeding, so the decision often comes down to individual circumstances rather than one being definitively better than the other.